Compare Recursion Pharmaceuticals Inc (RXRX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Western Alliance Bancorporation is far larger — about 5.8× Recursion Pharmaceuticals Inc's market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WAL | |
|---|---|---|
Market Cap | $1.53B | $8.84B |
Sector | Health | Financials |
52-Week High | $6.79 | $96.08 |
52-Week Low | $2.84 | $66.70 |
Enterprise Value | $946.50M | — |
Dividend Yield | — | 2.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
